Gelsectan®, Noventure´s new medical device intended for IBS-D, was presented at Noventure´s stand during the 3rd Meeting of the Federation of Neurogastroenterology and Motility, from 29 August to 1 September 2018 in Amsterdam, The Netherlands.
An observational study showing significant symptoms´ improvement in patients with IBS-D treated with Gelsectan® in Spain was presented in the poster session.
Moreover, Noventure hosted a meeting of experts with top European thought leaders in the field of IBS. The faculty agreed on the promising potential of Gelsectan® in the management of IBS-D patients.
Gelsectan® is a class IIa medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE 0476, Noventure SL).
In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.